Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278339 | 0.88 | TRPV1 (0.53) | TRPV1OPRM1 | |
| SCHEMBL14278338 | 0.84 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL13613606 | 0.84 | TRPV1 (0.59) | TRPV1OPRM1 | |
| SCHEMBL13613609 | 0.83 | TRPV1 (0.51) | TRPV1OPRM1 | |
| SCHEMBL13613607 | 0.83 | TRPV1 (0.53) | TRPV1OPRM1 | |
| SCHEMBL30385365 | 0.82 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL30385657 | 0.82 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL8672558 | 0.82 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL13613615 | 0.82 | TRPV1 (0.57) | TRPV1OPRM1 | |
| SCHEMBL4336879 | 0.82 | TRPV1 (0.52) | TRPV1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | TRPV1 10/4885OPRM1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.